Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer

Sponsor
Canadian Cancer Trials Group
Study ID
NCT02870920
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The standard or usual treatment for this disease is treatment with drugs and other treatments that may help to make a patient better or may improve their quality of life. This treatment is known as "best supportive care" (BSC). Although patients with best supportive care can feel better for some months, the cancer usually continues to grow.

Key Dates

Start date
Oct 12, 2016
Status verified
Jun 2022
Primary completion
Oct 18, 2018
Completion
Jun 7, 2022

Study Design

Enrollment
180 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Best Supportive Care
    Best supportive care available
  • Experimental: Durvalumab plus Tremelimumab and Best Supportive Care
    Tremelimumab 75mg IV 60 minutes Day 1, cycles 1-4 Durvalumab 1500mg IV 60 minutes Day 1 every 28 days. Plus best supportive care

Primary Outcome Measure

Overall Survival [ Time Frame: 24 months ]

Related Studies